Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Theravance Biopharma, Inc.TBPH · Entity 5037 | SVP, PROD STRAT & COMM PLNG | February 18, 2022 | February 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Theravance Biopharma, Inc.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 380,123 |
Reported balance
After 2022-02-18 transaction · row 1
1 source rowRow 1 · 2022-02-18 · Tax withholding · Disposed 27,299 · Balance 380,123 F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 23, 2022 18:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 27,299 | $9.61 | $262,343.39 |
DisclosureSEC source: 0001415889-22-001701 · form4-02232022_030237.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, PROD STRAT & COMM PLNG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,123 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 17:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001184 · form4-02092022_020249.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, PROD STRAT & COMM PLNG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,422 Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 20:24 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,310 | $8.36 | $36,031.60 |
DisclosureSEC source: 0001415889-21-005469 · form4-11232021_051103.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, PROD STRAT & COMM PLNG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,422 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 18:59 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,307 | $14.05 | $60,513.35 |
DisclosureSEC source: 0001179110-21-008398 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,732 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2021 Filed May 24, 2021 18:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,310 | $17.80 | $76,718.00 |
DisclosureSEC source: 0001179110-21-005846 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,039 Read SEC document |
| February 20, 2021 Filed Feb 23, 2021 18:10 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 31,931 | $18.79 | $599,983.49 |
DisclosureSEC source: 0001179110-21-002167 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 368,349 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 17:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001538 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,280 Read SEC document |
| November 20, 2020 Filed Nov 24, 2020 18:19 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,807 | $17.21 | $82,728.47 |
DisclosureSEC source: 0001179110-20-011371 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,280 Read SEC document |
| August 20, 2020 Filed Aug 24, 2020 18:29 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,804 | $18.22 | $87,528.88 |
DisclosureSEC source: 0001179110-20-009269 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,087 Read SEC document |
| May 20, 2020 Filed May 22, 2020 18:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,807 | $26.67 | $128,202.69 |
DisclosureSEC source: 0001179110-20-006528 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,891 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 19:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 29,136 | $25.90 | $754,622.40 |
DisclosureSEC source: 0001179110-20-002150 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,698 Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 19:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 54,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001204 · edgar.xml · nonDerivative · entry 2 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,834 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 3, 2020, the performance conditions applicable to 54,000 shares were achieved and such shares will vest on February 20, 2021, subject to the reporting person's continued service. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 19:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001204 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,834 Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 18:23 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $17.60 | $39,987.20 |
DisclosureSEC source: 0001179110-19-012017 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,834 Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 18:03 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $21.51 | $48,870.72 |
DisclosureSEC source: 0001179110-19-009792 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,106 Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 2,272 | $19.84 | $45,076.48 |
DisclosureSEC source: 0001179110-19-006527 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,378 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 18:18 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,674 | $27.00 | $99,198.00 |
DisclosureSEC source: 0001179110-19-002424 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,650 Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:47 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001567 · edgar.xml · nonDerivative · entry 2 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,324 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On February 5, 2019, the performance conditions applicable to 47,250 shares were achieved and such shares will vest on February 20, 2020, subject to the reporting person's continued service. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 17:47 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001567 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,074 Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 17:45 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 3,908 | $24.79 | $96,879.32 |
DisclosureSEC source: 0001179110-18-013109 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,074 Read SEC document |
| August 20, 2018 Filed Aug 22, 2018 19:34 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,043 | $26.95 | $135,908.85 |
DisclosureSEC source: 0001179110-18-010821 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,982 Read SEC document |
| May 20, 2018 Filed May 22, 2018 19:02 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 18,779 | $24.31 | $456,517.49 |
DisclosureSEC source: 0001179110-18-007374 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,025 Read SEC document |
| May 14, 2018 Filed May 16, 2018 19:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006938 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,804 F1 · shares: On March 15, 2016, the reporting person was granted a performance stock award that vests based on the achievement of certain performance conditions over a five-year timeframe from 2016 through December 31, 2020 and continued employment. On May 14, 2018, the performance conditions applicable to 33,750 shares were achieved and such shares will vest on May 20, 2018. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:40 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 4,252 | $29.09 | $123,690.68 |
DisclosureSEC source: 0001179110-18-002611 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,054 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 18:21 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002125 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,306 Read SEC document |
| November 20, 2017 Filed Nov 22, 2017 16:39 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,014 | $28.58 | $143,300.12 |
DisclosureSEC source: 0001179110-17-014565 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,306 Read SEC document |
| August 20, 2017 Filed Aug 22, 2017 18:30 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,013 | $27.40 | $137,356.20 |
DisclosureSEC source: 0001179110-17-011750 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,320 Read SEC document |
| May 20, 2017 Filed May 23, 2017 20:00 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 5,014 | $36.83 | $184,665.62 |
DisclosureSEC source: 0001179110-17-007880 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,333 Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 19:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 10,030 | $33.78 | $338,813.40 |
DisclosureSEC source: 0001179110-17-002993 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,347 Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 19:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002001 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,377 Read SEC document |
| November 20, 2016 Filed Nov 22, 2016 18:04 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 1,727 | $31.96 | $55,194.92 |
DisclosureSEC source: 0001179110-16-031979 · edgar.xml · nonDerivative · entry 1 PITZER KENNETH R · CIK 0001668775 · SVP, Prod Strat & Comm Plng 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,377 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.